Treatment of Chronic Hepatitis C in Children With Intron Vial or Pen [interferon alfa-2b] and Rebetol [ribavirin] According to German Law (67 Abs 6 AMG).

Trial Profile

Treatment of Chronic Hepatitis C in Children With Intron Vial or Pen [interferon alfa-2b] and Rebetol [ribavirin] According to German Law (67 Abs 6 AMG).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 02 Sep 2009 Planned end date changed from Oct 2009 to Jun 2007 as reported by ClinicalTrials.gov.
    • 02 Sep 2009 Actual number of patients (3) added as reported by ClinicalTrials.gov.
    • 20 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top